1. Home
  2. Browse
  3. National Institutes of Health
  4. PAR-25-321

PAR-25-321National Institutes of HealthR21

Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)

Deadline
Award ceiling
Not stated
Awards
Not stated
Posted
Dec 10, 2024

Official announcement on the NIH Guide · opens the funder's page. Always confirm dates there.

Or read the full text and all 3 review criteria here, free with an account. Create free account

Summary

The purpose of this engineering-oriented notice of funding opportunity (NOFO) announcement is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or…

Related NIH announcements3

Companion announcements with the same title first, then other open R21 announcements on related subjects with at least two weeks to go.

Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)

PAR-25-346National Institutes of Health3 review criteria on file

—

NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)

PA-25-306National Institutes of Health3 review criteria on fileagency framework

—

INCLUDE Project: Exploratory/Developmental Research Awards for Down syndrome (R21 Clinical Trial Not Allowed)

RFA-OD-27-003National Institutes of Health3 review criteria on fileagency framework

$200k

The full announcement, free with an account

  • The full announcement text, not just the first two sentences
  • All 3 review criteria reviewers score this against, extracted from this announcement

On Plus, $39 a month

  • The eligibility check against your profile: career stage, institution type, and the windows that close before the deadline does
  • Funded precedents: what similar NIH projects received, from the award records in NIH RePORTER
  • A Reviewer Scorecard of your draft against these criteria
Create free accountSign in

No card required. Browsing is free.

Subjects

More from National Institutes of Health

Open now with at least two weeks to apply, soonest deadline first.

NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

PAR-25-057National Institutes of Health6 review criteria on file

—

Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)

RFA-DK-27-108National Institutes of Health3 review criteria on fileagency framework

$500k

Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)

RFA-DK-27-139National Institutes of Health

—

Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)

RFA-DK-27-112National Institutes of Health

—

Everything open from National Institutes of Health

Related by subject

Open opportunities sharing the most subjects with this one (Clinical research), with at least two weeks to apply.

NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

PAR-25-188National Institutes of Health3 review criteria on file

$500k

Continuation or Revision of NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UH3 Clinical Trial Required)

PAR-25-062National Institutes of Health6 review criteria on file

—

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)

RFA-NS-26-001National Institutes of Health3 review criteria on file

—

Everything open tagged Clinical research

Source record: https://grants.nih.gov/grants/guide/pa-files/PAR-25-321.htmlVia the NIH Guide. Last checked against the source . Always confirm dates with the funder.